Accelmed

GT Medical Technologies develops and manufactures a novel medical device for treating brain tumors. Its flagship product, GammaTile™, combines a conformable collagen matrix with brachytherapy seeds to deliver targeted radiation therapy, potentially revolutionizing treatment for over 176,000 patients annually in the U.S. The company's focus is improving patient outcomes and quality of life.

Bioventus - Advanced Rehabilitation Business is a unit of Bioventus that provides rehabilitation and healthcare services to patients.

Revamp Medical, founded in 2016, is dedicated to addressing the critical unmet needs of patients suffering from acute heart failure. With over one million annual admissions in the United States and associated costs exceeding $65 billion, the company aims to provide an innovative solution through its patented temporary catheter, Doraya™. This device regulates vascular hemodynamics, particularly for patients experiencing diuretic resistance, by managing preload and reducing central venous pressure. This functionality enhances diuretic efficacy and facilitates progressive decongestion, thereby allowing cardiologists to effectively manage key hemodynamic parameters. Revamp Medical is supported by a skilled team with extensive experience in the medical technology sector, positioning the company to make a significant impact in the treatment of acute heart failure.

Minerva Surgical Inc. is a medical technology company based in Redwood City, California, dedicated to women's healthcare. Founded in 2008, the company specializes in developing, manufacturing, and commercializing minimally invasive solutions for uterine health. Its flagship product, the Minerva Endometrial Ablation System, is designed to treat abnormal uterine bleeding, a common issue affecting many women. Minerva Surgical offers a comprehensive range of alternatives to hysterectomy, aiming to address the underlying causes of abnormal uterine bleeding while preserving the uterus. These solutions are applicable in various medical environments and seek to overcome the limitations of traditional treatment methods, providing women with effective and less invasive options for their healthcare needs.

MedMinder Systems, Inc. is a company that specializes in developing innovative solutions for medication management and adherence support. Founded in 2007 and headquartered in Needham, Massachusetts, the company offers a range of products including automatic pill dispensers that remind users of their medication schedules through visual and auditory alerts, as well as notifications sent to caregivers and pharmacists. MedMinder's offerings include various types of pill dispensers, locked dispensers, medical alert products, and pre-filled medication trays. The company serves a diverse customer base across several states, including Massachusetts, New York, Florida, and others. Through its services, MedMinder aims to simplify the process of taking medications, thereby improving adherence and enhancing patient care.

MedMinder Systems, Inc. is a company that specializes in developing innovative solutions for medication management and adherence support. Founded in 2007 and headquartered in Needham, Massachusetts, the company offers a range of products including automatic pill dispensers that remind users of their medication schedules through visual and auditory alerts, as well as notifications sent to caregivers and pharmacists. MedMinder's offerings include various types of pill dispensers, locked dispensers, medical alert products, and pre-filled medication trays. The company serves a diverse customer base across several states, including Massachusetts, New York, Florida, and others. Through its services, MedMinder aims to simplify the process of taking medications, thereby improving adherence and enhancing patient care.

Veranex is a global service provider that specializes in the medical technology sector, offering comprehensive, technology-enabled solutions from concept to commercialization. The company focuses exclusively on various areas within medical technology, including medical devices, diagnostics, companion diagnostics, digital health, and drug delivery. Veranex provides a wide range of services, such as design and engineering, regulatory support, clinical trials, and market access, enabling clients to streamline their development processes. By addressing the entire clinical trial journey, Veranex helps clients accelerate their time to market, enhance market viability, manage development costs, and reduce associated risks.

Click Therapeutics is a New York‑based company that develops and commercializes digital therapeutics that use cognitive and neurobehavioral techniques to treat a range of medical conditions. Its platform personalizes treatment through an adaptive data science engine, aiming to improve engagement and clinical outcomes. The company’s flagship smoking‑cessation program has been approved for nationwide use and is available through payers, providers, and employers. It is also conducting a phase III FDA‑registered trial for a prescription digital therapy for major depressive disorder. Other indications under development include schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Founded in 2012, Click Therapeutics focuses on delivering software as a medical treatment that can be used independently or alongside conventional therapies.

Founded in 2006, Keystone Dental is a leading oral healthcare company specializing in the manufacture and distribution of dental implants, biomaterials, and planning software for dental professionals. Its product portfolio includes a range of bone grafting solutions and resorbable membranes. The company is committed to improving patient care and quality of life through innovative, high-quality products.

TailorMed Medical Ltd., established in 2017 and based in Tel Aviv, Israel, specializes in health IT solutions. The company develops and provides financial navigation technology and systems, designed to streamline and automate financial processes for both patients and healthcare providers. Their offerings include TailorMed Financial Navigation, a platform to manage and automate financial processes; TailorMed Financial Insights, an analytics and reporting dashboard to track and measure key performance indicators; and TailorMed Pharmacy, a platform to simplify drug ordering, tracking, and billing based on patient treatment regimens.

Memic Innovative Surgery develops and delivers robotic surgical solutions designed to enable otherwise infeasible surgical procedures. Its first offering facilitates a variety of robotic gynecological procedures via a vaginal approach, expanding the feasibility of vaginal surgery to the vast majority of cases. Its robotic technology consists of miniature and humanoid-shaped articulated arms that mimic human dexterity while surpassing human flexibility. The robotic arms are controllable via various proprietary control consoles to maintain natural control of the arms, allowing surgeons to operate precisely in tight anatomical spaces with decreased risk to nearby organs and tissue.

MedMinder Systems, Inc. is a company that specializes in developing innovative solutions for medication management and adherence support. Founded in 2007 and headquartered in Needham, Massachusetts, the company offers a range of products including automatic pill dispensers that remind users of their medication schedules through visual and auditory alerts, as well as notifications sent to caregivers and pharmacists. MedMinder's offerings include various types of pill dispensers, locked dispensers, medical alert products, and pre-filled medication trays. The company serves a diverse customer base across several states, including Massachusetts, New York, Florida, and others. Through its services, MedMinder aims to simplify the process of taking medications, thereby improving adherence and enhancing patient care.

NeuroPace designs and markets implantable neuromodulation systems for neurological disorders, with a focus on epilepsy. Its flagship RNS System includes an implantable neurostimulator connected to depth and cortical leads that monitor brain activity and deliver targeted, responsive electrical stimulation to seizure onset regions. External components, including a programmer and software, enable device configuration and monitoring. Founded in 1997 and based in Mountain View, California, the company generates most revenue from selling RNS Systems to hospital facilities for implantation in patients with medically refractory partial epilepsy. NeuroPace aims to reduce or eliminate seizures through adaptive neuromodulation.

TearLab Corporation is an in-vitro diagnostic company based in Escondido, California, specializing in the development and marketing of innovative tear testing technologies for the diagnosis of dry eye disease. The company’s flagship product, the TearLab Osmolarity System, is a proprietary platform that allows eye care practitioners to measure tear film osmolarity and identify sensitive biomarkers using only nanoliters of tear film at the point-of-care. This system includes a disposable microfluidic chip, a hand-held device known as the TearLab Pen for sample collection, and the TearLab Reader, a desktop unit that provides quantitative results. Founded in 1996, TearLab aims to enhance the standard of care in ophthalmology through objective and precise testing methodologies.

BioProtect specializes in developing and commercializing biodegradable balloon spacers to protect normal tissue during cancer radiation therapy. Its flagship product, ProSpace, has demonstrated superior efficacy and safety in protecting the rectum during prostate cancer radiotherapy. BioProtect's technology platform caters to a wide range of applications for unmet clinical needs.

Diagnostic Robotics develops an artificial intelligence system for healthcare insurers, providers, and patients. Founded in 2017 and based in Tel Aviv, Israel, the company creates predictive analytics models to address clinical and financial challenges in healthcare. These models aim to optimize clinical program performance, increase return on investment, and enable more effective care at lower costs by allowing for informed decisions and proactive interventions.

EndoGastric Solutions, Inc. is a medical device company focused on developing and commercializing innovative surgical technologies for the treatment of gastrointestinal diseases, particularly gastroesophageal reflux disease (GERD). The company offers products such as EsophyX, which enables transoral reconstructive surgery, and the EsophyX Z device used in the transoral incisionless fundoplication procedure. Additionally, EndoGastric Solutions provides SerosaFuse Fasteners, a non-resorbable polypropylene material with strength comparable to traditional sutures. Beyond its product offerings, the company supports healthcare professionals through trainer-led courses and various consultative services, including pre-authorization and medical review. Founded in 2002 and headquartered in Redmond, Washington, with an additional office in San Mateo, California, EndoGastric Solutions was previously known as EsophyX, Inc. before its rebranding in January 2005.

Strata Skin Sciences is a medical technology company focused on dermatology, developing, marketing, and distributing devices for treating skin conditions. Its product portfolio centers on the XTRAC excimer laser and VTRAC lamp systems used to treat psoriasis, vitiligo, eczema, and related disorders. The company operates two segments: Dermatology Recurring Procedures, deriving revenue from ongoing use of its devices by dermatologists, and Dermatology Procedures Equipment, from sales of equipment. Distribution is international through distributors and domestic direct sales to physicians. Headquartered in Horsham, Pennsylvania, Strata Skin Sciences traces its origins to 1989.

Cogentix Medical designs, manufactures, and markets a range of high-performance fiberoptic and video endoscopy products under the PrimeSight brand. These products serve multiple surgical specialties in diagnostic and treatment procedures worldwide. The company's portfolio includes endoscopes for medical use, borescopes for industrial use, digital processing units, and other specialized devices such as the EndoSheath Protective Barrier and the Urgent PC System for neuromodulation. Cogentix Medical was established through a merger in 2015.

SoniVie is a medical device company focused on developing innovative solutions for the treatment of pulmonary hypertension. The company has created a minimally invasive denervation device that is designed to be inserted into the pulmonary artery through a catheterization procedure. This advanced technology selectively targets and damages the nerves associated with pulmonary hypertension, while preserving the integrity of the vessel walls and surrounding tissues. By enabling physicians to perform denervation procedures with greater precision, SoniVie aims to improve treatment options and outcomes for patients suffering from this serious condition.

Eximo Medical Ltd. is an innovative company based in Modi'in-Maccabim-Re'ut, Israel, specializing in hybrid catheter technology for tissue resection in vascular and gastrointestinal endoluminal applications. Founded in 2012, Eximo has developed a proprietary single-use hybrid catheter known as CatHI, which integrates optical fibers that emit short laser pulses and a blunt mechanical knife. This advanced technology aims to enhance safety and performance during medical procedures, particularly in atherectomy, by minimizing the risk of vessel perforation. As of October 2019, Eximo Medical operates as a subsidiary of AngioDynamics, Inc.

Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.

EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Corvia Medical, Inc., established in 2009 and based in Andover, Massachusetts, is a medical device company specializing in structural heart devices for heart failure treatment. Its primary product is the InterAtrial Shunt Device (IASD), a transcatheter device designed to alleviate symptoms and slow the progression of diastolic heart failure, also known as heart failure with preserved ejection fraction (HFpEF). The IASD system reduces elevated left atrial pressure, the primary cause of DHF symptoms, by creating a small opening between the left and right atria, enabling patients to lead healthier lives with reduced heart failure risk.

CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.

Digma Medical is a clinical stage medical device company focused on innovative treatments for Type-2 Diabetes and related metabolic disorders, including NASH. Founded in 2013, the company is developing the DiaGone™, a disposable endoscopic device that employs advanced laser technology to target the duodenum, the first section of the small intestine. This device is designed to address insulin resistance, the core issue in these diseases. The Duodenal Glycemic Control™ procedure, which lasts approximately 30 minutes, allows gastroenterologists to utilize the DiaGone™ to enhance the body's natural ability to regulate glucose levels. This approach aims to offer patients the potential for long-term remission from Type-2 Diabetes and improve overall health outcomes.

EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Valcare, Inc., established in 2012 and headquartered in Irvine, California, specializes in the design and development of medical devices and accessories for minimally invasive treatment of heart valve disease. The company's core technology is a transcatheter platform that functions as a docking station for replacement prostheses and a tool for mitral annulus repair, aiming to improve treatment options and accelerate recovery for patients with mitral and tricuspid regurgitation.

CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.

NLT Spine is a clinical stage company focused on developing and marketing innovative products for Minimally Invasive Spinal Surgery (MISS), aimed at treating degenerative spinal conditions. By utilizing non-linear technology, NLT Spine creates instruments and implants specifically designed for lumbar interbody fusion procedures and other surgical treatments of back pain. The company is dedicated to enhancing patient care by transitioning from traditional open surgical methods to more advanced, minimally invasive techniques that improve safety, predictability, and clinical outcomes.

CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.

Pi-Cardia is a medical device start-up focused on developing an innovative low-profile catheter for the treatment of aortic stenosis. The company's proprietary technology utilizes a trans-femoral catheter that incorporates nitinol elements to deliver mechanical impact, creating fractures in calcified heart valves without damaging the surrounding soft tissue. This rapid treatment approach aims to enhance the effective orifice area of the valve, providing a cost-effective and durable solution that eliminates the need for valve replacement. By addressing the challenges associated with aortic stenosis, Pi-Cardia seeks to improve patient outcomes and streamline the treatment process for healthcare providers.

EndoChoice is a medical device company specializing in the development and commercialization of technologies for gastrointestinal (GI) care. Founded in 2008 and headquartered in Alpharetta, Georgia, the company offers a range of products that include single-use devices, diagnostics, infection control products, and endoscopic imaging systems tailored for GI specialists. One of its notable innovations is the Full Spectrum Endoscopy™ System, which features colonoscopes and gastroscopes equipped with multiple imagers, allowing for a wider field of view compared to traditional endoscopes. This technology has demonstrated its efficacy by detecting significantly more polyps during colonoscopy procedures. EndoChoice serves over 2,000 customers in the United States and collaborates with 34 distribution partners globally. The company was recognized by Inc. Magazine as one of the fastest-growing companies in the U.S. for four consecutive years prior to its acquisition by Boston Scientific in 2016.

Medical Compression Systems (MCS) Ltd. provides solutions for the prevention of deep vein thrombosis (DVT) and venous thromboembolism (VTE). The company’s product pipeline includes ActiveCare+S.F.T., a non-pharmaceutical mechanical solution that provides the prevention of DVT/VTE for in and out of hospital patient settings; and ActiveCare+DTx, which prevents DVT, as well as identifies proximal venous flow obstruction. Its product pipeline also comprises the ActiveCast, a device for bone fracture treatment; and the ActiveCare Vascular, a device used in the outpatient wound care market.

CartiHeal Ltd. is a medical device company based in Kfar Sava, Israel, specializing in the development of innovative solutions for cartilage and bone disorders. Founded in 2009, the company has pioneered a cell-free implant technology known as Agili-C, designed to address focal articular cartilage and osteochondral defects. This off-the-shelf implant promotes the regeneration of true hyaline cartilage and its underlying subchondral bone through a minimally invasive procedure, without the need for cells or growth factors. CartiHeal's Agili-C implant represents a significant advancement in the treatment of cartilage injuries, which can lead to severe pain, disability, and early onset of osteoarthritis if left untreated. By offering a well-tolerated and effective solution, CartiHeal aims to meet a critical need in the field of cartilage repair and regeneration.